Overview

About Global Biopharma, Inc. (GBP) 

Global BioPharma, Inc. (GBP) is a clinical-stage biotechnology company focused on developing cancer immunotherapies that take advantage of the body's natural immune system, redirecting the immune responses to target cancer cells. GBP was founded in October 2013. GBP was initiated by a group of seasoned executives with extentive experiences in research, clinical trials,  chemistry, manufacturing, controls and business development with the financial supports of venture capitals and individual investors led by Taiwan Biotech Co., Ltd (TBC).

GBP is dedicated to develop immunotherapy ADXS-HPV for the treatment of HPV-associated cancers. Licensed from Advaxis, Inc. (NASDAQ: ADXS), GBP obtained the rights to develop, manufacture, market and sell ADXS-HPV, an immunotherapy, in Asia (other than India), the former Soviet Union and most African countries. Our business territory covers 84 countries with over 3.8 billion people.

GBP will be responsible for the cost of all clinical deveopment and commercialization for ADXS-HPV immunotherapy in the designated territory:

 

• GBP will partner with Advaxis to conduct registration trials of ADXS-HPV for the treatment of advanced cervical cancer.
• GBP will conduct a phase I/II trial of ADXS-HPV for the treatment of HPV+ lung cancer. 
• GBP will partner with Advaxis to explore the use of ADXS-HPV as a treatment for other diseases, including head, neck and anal cancers.

GBP is committed to establishing manufacturing capabilities for the designated territory and to serving as a secondary manufacturing source for Advaxis in the future.
 

About ADXS-HPV Immunotherapy

ADXS-HPV is a live attenuated Listeria monocytogenes (Lm)-LLO immunotherapy that has been developed to treat HPV-associated cancers.  ADXS-HPV has been bioengineered to secrete an antigen-adjuvant fusion (tLLO-E7) protein consisting of a truncated fragment of listeriolysin O (tLLO) fused to HPV16-E7. The proposed mechanism of action is that the Lm vector serves as its own adjuvant and stimulates strong innate and adaptive immune responses to specifically target tumor dysplastic cells by recognizing tumor associated antigen (HPV 16-E7).

About Taiwan Biotech Co., Ltd. 
Taiwan Biotech Co., Ltd. (TBC) is the lead investor of GBP.  TBC is one of the top five pharmaceutical companies in Taiwan. TBC is involved in the research, development, manufacturing, representation, and distribution of pharmaceutical drugs, medical devices, and active pharmaceutical ingredients. The company offers health care products, including pharmaceutical drugs, antimicrobial agents, anti-diabetic agents, amino acid agents, external agents, syrups, ophthalmic agents, antibiotics, neuromuscular disorder drugs, and injections, as well as vitamin preparations. TBC currently has relationships with Teva (as a result of its acquisition of Cephalon), Taisho Pharmaceutical, Towa Pharmaceutical, PolyPeptide Laboratories, Sunward Pharmaceutical, and Besins Healthcare Ltd.

About Advaxis, Inc. 
Advaxis, Inc. (NASDAQ: ADXS) is a clinical-stage biotechnology company developing the next generation of cancer immunotherapies.  Advaxis immunotherapies are based on a novel platform technology using live attenuated bacteria that are bio-engineered to secrete an antigen-adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacteriumto the cancer itself.